People who join the study will apply the cream to affected skin areas twice each day for about four months. During this time they will attend regular clinic visits where doctors will look at the skin and record changes using a scoring system called mSWAT, which rates how much of the skin is involved and how severe the patches are. Participants will also answer simple questionnaires about itching (called pruritus) and how the skin condition affects daily life. Small skin samples may be taken to explore how the medicine works, and a gentle test may be performed to see if the skin barrier improves. The study ends after the treatment period, and the collected information helps researchers understand whether the cream is safe and how well it works for this condition.

The purpose of the study is to determine which of these treatments leads to a shorter stay in the hospital for patients whose infection does not improve with the initial antibiotics and drainage. After a patient is enrolled, they receive either the surgical procedure or the medication combination, stay in the hospital while doctors watch for improvement, and are then followed for about a month to see how quickly they can leave the hospital and return to normal activities.

During the follow‑up, information is collected on how long the chest tube remains, any need for additional procedures, pain levels, ability to perform daily tasks, and overall quality of life. The study also looks at the costs related to health care and any loss of work time, helping to understand the broader impact of each treatment option.

The purpose of the study is to find out if the addition of the blood thinner provides more benefit than harm in these patients. Participants are randomly assigned to either receive a daily 5 mg dose of apixaban or to receive no extra blood‑thinning medication while they undergo their standard cancer treatment. Throughout the treatment period, patients have regular check‑ups and a special X‑ray picture called a CT scan to look for any clots or serious bleeding. The term major bleeding refers to serious bleeding that may need a blood transfusion, occur in a vital organ, cause a large drop in blood‑protein levels (hemoglobin), or be life‑threatening.

After the neoadjuvant therapy and before the definitive surgery or radiation, patients continue to be monitored for several months to see if clots or serious bleeding occur, and longer‑term follow‑up looks at overall survival and cancer‑specific outcomes.

The purpose of the study is to describe how well proportional sedation with transmucosal midazolam works and how well it is tolerated in pediatric palliative patients who have refractory symptoms.

Participants will receive the medication as prescribed, with regular observations to see how the symptoms respond and to monitor safety. The study follows each child for a period of time, collecting information on symptom relief and any side effects, before concluding the observation phase.

The purpose is to determine whether allowing patients to choose their treatment reduces feelings of regret about that choice after twelve months. Participants are randomly placed into either the choice group or the surgery‑only group, receive the assigned treatment, and are followed for about a year with regular check‑ups.

During follow‑up, patients answer questions about any regret regarding the initial treatment, report any return of symptoms, and complete a questionnaire about overall quality of life. This information is used to compare the outcomes of the two treatment strategies.

The purpose of the study is to determine whether a three‑month course of MPD can improve thinking, attention, and overall quality of life compared with a control pill, which is a placebo. The trial is designed so that neither the participants nor the investigators know who receives the active drug or the control pill, ensuring an unbiased comparison.

Participants will take study tablets daily for three months and attend regular visits where simple brain‑activity recordings (explained as tests that measure the brain’s electrical signals) and mental‑function assessments (explained as tests that evaluate memory, problem‑solving, and attention) are performed, along with questionnaires about daily living and wellbeing.

During the scan, a short‑acting medicine is given through an IV to make the heart work a little harder, allowing doctors to see how the blood vessels respond. The medicines used are Adenosine and regadenoson, both of which safely cause a temporary rise in heart workload. A small amount of a harmless radioactive substance, O15-water, is also injected so the scanner can create detailed pictures of blood flow. The amount of blood moving through the heart muscle is expressed as MBF, which helps identify areas that may not be getting enough oxygen.

The purpose of the study is to find specific numbers that can predict the chance of future major heart problems, known as MACE. Participants undergo the PET scan with the stress medicines, then are followed for several years while information about any heart attacks, deaths, or related events is recorded. This follow‑up helps determine which scan results are linked to higher or lower risk.

The purpose of the trial is to see whether giving tranexamic acid during surgery changes the rate of post‑operative infections within one year. After the procedure, participants are followed for up to twelve months with check‑ups at two weeks, three months and one year. During these visits doctors look at how the wound is healing, whether the skin has opened up (wound dehiscence), how much blood loss occurred by measuring blood‑type protein levels, and if any additional surgery is needed. Bone healing (fusion) is checked at the final visit using a special imaging test called computed tomography, which produces detailed pictures of the bones. All participants receive the same standard care apart from the study medication, and the study records any infections, wound problems, extra surgeries, and the overall success of the bone fusion.

People in the study will have either closed wounds, such as stitched cuts, or open wounds, such as small biopsy wounds made during the study. After treatment, the wounds will be followed over time while they heal, and the scars will be checked later. The study will also look at how safe the treatment is and whether any side effects occur, such as skin reactions or other body reactions. Some scars will also be looked at with medical pictures and ultrasound, which is a test that uses sound waves to create images inside the body.

Scar prevention is the main focus of this trial, and the study is designed to compare three verteporfin doses with saline in both open and closed wound types. The study will continue until the healing and scar checks are completed after treatment.

The purpose of the study is to determine whether the drug can improve kidney function compared with placebo. Kidney function will be assessed by measuring how well the kidneys filter waste, using a test called creatinine clearance, during the first few hours after the infusion starts.

After the surgery, eligible infants are randomly assigned to receive the study medication or placebo. The infusion is given over a short period, and blood and urine samples are collected for safety checks and to evaluate kidney performance. The children are then observed for about two days to monitor urine output, fluid balance, and any signs of kidney problems, with follow‑up continuing until the study ends.

The purpose of the study is to determine whether this cell‑based therapy can improve how long patients live without the disease getting worse and ultimately increase overall survival. After the chemotherapy course, the cell infusion is administered, followed by surgery to remove the tumor when possible. Patients are then monitored over time to see if the cancer returns, using imaging criteria called RECIST 1.1, and to assess quality of life and safety. The follow‑up period includes regular doctor visits, scans, and blood tests to track the immune response and any side effects.

Participants in the study will be divided into two groups. One group will receive meropenem through an intravenous infusion, which is a method of delivering medication directly into a vein. The other group will receive a placebo consisting of sodium chloride, a common salt solution. This process is conducted as a double-blind trial, meaning neither the patients nor the medical staff know which substance is being administered during the treatment period.

During the course of the study, medical professionals will monitor how the body responds to the treatment. The focus will be on observing survival rates and checking for organ dysfunction, which refers to a situation where vital organs such as the kidneys, liver, or lungs are not working correctly. The study will also track how long patients remain in the hospital and the overall progress of the illness following the administration of the medication.

The purpose of the study is to determine how well this new drug works and to monitor its safety in people with this condition. During the study, participants will receive the medication, and their health will be closely monitored. This includes checking for any side effects and observing how the cancer responds to the treatment over time.

The treatment being studied involves the use of fludarabine phosphate, which is administered through an intravenous line, meaning it is delivered directly into a vein. This medication is used alongside cyclophosphamide as part of the preparation process. The study also takes into account patients who have previously received or are scheduled to receive other specialized cell therapies, such as tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, or ciltacabtagene autoleucel. The goal is to understand the pharmacokinetics, or how the drug moves through, is absorbed by, and is eliminated from the body.

During the course of the study, blood samples will be collected to measure the levels of the medication in the blood over time. These measurements help determine the maximum observed concentration and the overall exposure to the drug. Researchers will also look at various patient factors, such as weight and kidney function, to see how they might relate to how the body handles the medication.

During the study, participants will be given either sodium hydrogen carbonate or a comparison solution containing electrolytes, such as sodium chloride, calcium chloride dihydrate, potassium chloride, or magnesium chloride hexahydrate. These comparison solutions include options like Jonosteril Infusionslösung, Sterofundin ISO Infusionslösung, and Ringer-Infusionslösung B. Braun. The study monitors various health outcomes over a 90-day period, including the need for kidney replacement therapy, which refers to treatments like dialysis that perform the work of the kidneys, and changes in creatinine levels, a substance in the blood used to measure how well the kidneys are functioning.

Participants in the study will be assigned to receive either empagliflozin or a placebo. The treatment involves taking a 10 mg film-coated tablet once daily. During the study, various factors such as body weight, blood pressure, and levels of substances like sodium, potassium, and bicarbonate in the blood and urine will be monitored. Additionally, the HbA1C, which is a measure of average blood sugar levels over time, will be tracked throughout the process.

The purpose of the study is to determine if this specific method of delivering medication is safe and practical for patients. During the study, the oxaliplatin is administered through an infusion, which is a process where medicine is delivered into the bloodstream through a tube. This delivery is done using an arterial access device, a small tool placed into an artery to allow medicine to be sent directly to the liver area.

The purpose of the study is to compare how the body processes these medicines when they are given under the skin compared to when they are given through a vein. During the study, patients will receive either the medicine under the skin or through a vein. Blood samples will be collected to measure the amount of medicine in the blood over time. This helps researchers understand if the medicine reaches the same levels in the body with both methods of giving it. The treatment period will last for up to ten days, and doctors will check how well the infection is responding to the treatment.

The study will also look at whether the medicine levels in the blood stay high enough to fight the infection effectively. Doctors will measure if the signs and symptoms of infection improve or go away without needing additional antibiotics. They will also check if the bacteria causing the infection are eliminated. Any side effects or unwanted reactions that occur during treatment and up to one day after treatment ends will be recorded. This information will help determine if giving these antibiotics under the skin is a safe and effective alternative to giving them through a vein.

The purpose of this study is to evaluate whether switching from antibiotics given through a vein to antibiotics taken by mouth earlier in the treatment process works as well as the standard longer treatment with intravenous antibiotics. The study will follow a standardized treatment plan that allows patients to switch to oral antibiotics after a short period of intravenous treatment. This approach aims to determine if patients can be treated effectively with oral medications, which would potentially allow them to complete treatment outside of the hospital setting while maintaining the same level of effectiveness in fighting the infection.

Patients participating in this study will initially receive intravenous antibiotics while admitted to the hospital for less than ten days. After this initial phase, if their condition is stable and the infection is responding to treatment, they may be switched to oral antibiotics according to the study protocol. Throughout the treatment period, which will last for up to six months, patients will be monitored for any signs that the infection is not responding, any complications, or side effects from the medications. The study will track various outcomes including survival, need for heart surgery, new infection-related complications, and patient satisfaction with the treatment approach. Blood samples will be collected at certain times to measure antibiotic levels and ensure the medications are working properly.

The purpose of this study is to check whether this treatment method is safe and practical for older and more fragile women with advanced ovarian cancer who may not be suitable for a similar treatment that uses heat. The study will look at how the treatment affects the body, including any side effects or complications that may occur during or after surgery. It will also measure how the drug moves through the body and how it affects both healthy tissue and cancer tissue in the abdominal area. Additionally, the study will examine how this treatment affects inflammation and blood flow in the tissues.

Women participating in this study will first receive chemotherapy before surgery to shrink the cancer. Then, during surgery to remove the cancer, they will receive carboplatin directly into the abdominal cavity. After surgery, they will be monitored for any complications and side effects. The study will track how long patients stay in the hospital, whether they need additional surgeries, and how soon they can start additional chemotherapy after surgery. The study will also look at quality of life through questionnaires and will measure various biological markers in both tissue samples and blood to understand how the treatment works. The entire study is expected to continue until 2027.

The purpose of this study is to find out which of these medications works best in reducing the severity of the condition in patients who have not improved with standard antibiotic treatments. The study will measure success by looking at whether there is a significant improvement in the severity of the disease after six months of treatment. This will be assessed using a scoring system that rates the overall appearance and severity of the condition, and the assessment will be done by someone who does not know which treatment the patient is receiving.

The study will last up to twelve months for each participant, with treatment being given for six months. During the study, patients will have regular visits to check how well the treatment is working and to monitor for any side effects. The study will also measure other important outcomes such as pain levels, itching, quality of life, and whether the condition comes back after treatment. If a patient’s condition worsens significantly during the study, they may receive antibiotic treatment as a rescue therapy. Patients will need to have had a recent chest x-ray before starting the study, and they must be between eighteen and sixty-five years old to participate.

The purpose of the study is to find out if treating uncomplicated candidemia, which means the infection has not spread to other parts of the body, for 7 days after the first blood test shows no more yeast is as effective as treating it for 14 days after that first clear blood test. The study will compare how many patients are alive 28 days after their first negative blood culture between the two treatment durations. Patients in the study will receive one of the antifungal medications mentioned above, and the length of treatment will depend on which group they are randomly assigned to.

During the study, patients will have blood tests to check their liver function and to confirm that the infection has cleared. The study will also track whether the infection comes back or spreads to other parts of the body. Patients will be followed for up to 45 days to monitor their recovery and check for any signs that the infection has returned. The study will also look at the costs associated with each treatment duration to understand the economic impact of the different approaches.

Patients participating in this study will have experienced persistent headaches for at least 24 hours despite receiving conservative treatment such as rest, fluids, and pain medication. They will receive either the sphenopalatine block or the blood patch procedure. After the treatment, headache intensity will be measured using a scale from zero to ten, where zero means no pain and ten represents the worst possible pain. These measurements will be taken at multiple time points: at the start of the procedure, then at 30 minutes, one hour, two hours, six hours, 24 hours, 48 hours, and seven days after treatment. The treatment period lasts one day, with follow-up assessments continuing for seven days.

The study will also track several other aspects of patient care and recovery. This includes monitoring how much pain medication patients need after the procedure, whether additional treatment with a blood patch becomes necessary, and how long patients need to stay in the hospital during the seven-day period following treatment. Any unwanted effects that occur during the procedure will be recorded, as well as any serious complications. Patient satisfaction with the treatment will be assessed seven days after the procedure using a rating scale. The study aims to determine whether the sphenopalatine block offers a comparable alternative to the blood patch for managing this painful condition.

The purpose of this study is to examine how well long-term maintenance treatment with ketamine works for keeping depression symptoms from coming back after an initial treatment period. The study is designed to compare different treatment approaches over time to see which one is most effective at preventing depression from returning. Participants will be divided into three different treatment groups to compare the results. The study will look at how long it takes for depression symptoms to come back after the initial treatment phase and after the last ketamine infusion, using a depression rating scale to measure symptom severity.

During the study, participants will receive ketamine infusions according to their assigned treatment group, with the treatment lasting up to 10 days in total. The maximum daily dose will be 150 milligrams, and the maximum total dose across all infusions will be 2700 milligrams. Throughout the study, doctors will monitor participants for any unwanted effects or reactions to the treatment through interviews, observations, questionnaires, and review of medical records. Women who could become pregnant must have a negative pregnancy test before starting the study and before each maintenance ketamine infusion, and must use highly effective birth control methods throughout their participation in the study.

The purpose of the study is to find out whether taking magnesium aspartate by mouth for eight days can reduce the occurrence of long-term hypoparathyroidism six months after surgery. Participants will be randomly assigned to receive either the magnesium supplement or placebo, and neither the participants nor the doctors will know which treatment is being given. The magnesium or placebo will be taken starting before the surgery and continuing for several days afterward. During the study, doctors will monitor calcium levels and parathyroid hormone levels in the blood to check how well the parathyroid glands are working.

Throughout the study period, which lasts up to six months after surgery, participants will be checked at different time points to see if they develop hypoparathyroidism and whether they need additional treatments such as calcium or vitamin D supplements. The study will also track any side effects or unwanted reactions to the treatment and ask participants about symptoms they may experience related to low calcium levels. This information will help researchers understand if giving magnesium before and after thyroid surgery can protect the parathyroid glands and prevent complications.

During the study, participants will receive a single injection of the study medication. The medication works by attaching to a specific protein called Carbonic Anhydrase IX that is often found on the surface of tumors related to this condition. After the injection, special imaging scans will be performed to see if the medication can help detect tumors in the body. This type of imaging is called CAIX-PET, which uses the study medication to create images that may show where tumors are located.

The study will look at how well this imaging method can find tumors in people with Von-Hippel Lindau disease and in people with certain types of tumors that can occur without the genetic condition. The study will also check the safety of using this imaging approach. Participants will be followed for a period of time after receiving the injection to monitor for any side effects and to complete the imaging procedures.

The main purpose of this study is to understand how the inhaled medication spreads throughout the lungs and to find the best way to give this treatment. During the study, special imaging called single-photon emission computed tomography will be used to see where the medication goes in the lungs. The researchers will also measure how much of the medication gets into the blood.

The treatment will be given over two days through a nebulizer. Throughout the study, the researchers will monitor how well patients tolerate the treatment and any side effects they may experience. They will also ask patients about their satisfaction with the treatment and how convenient it is to use.

The purpose of the study is to compare the outcomes of radiation treatment when planned using PSMA PET imaging versus standard imaging methods. The study involves two groups of patients – one group will receive radiation therapy planned using conventional imaging, while the other group will have their treatment planned using PSMA PET scans. Each participant will receive a single dose of the imaging agent before their radiation treatment planning.

During the study, patients will be monitored for several years to track their response to treatment and any changes in their cancer status. The monitoring includes regular check-ups and various tests to assess how well the treatment is working. The study medication (Locametz) is already approved for use in medical imaging and will be given as a single dose of up to 259 MBq (a measure of radioactivity).

The main purpose of this study is to determine if Treg02 treatment is safe and well-tolerated in liver transplant patients who are taking tacrolimus alone, and whether it can help patients eventually stop taking their anti-rejection medication. During the study, patients will receive paracetamol and dimetindene as supportive medications. The treatment involves taking blood from the patient, processing it to isolate and multiply specific immune cells in a laboratory, and then giving these cells back to the patient through an injection into a vein.

The study will monitor patients for any side effects from the treatment, particularly focusing on reactions to the cell infusion, infections, and signs of organ rejection. Patients will undergo regular check-ups, including blood tests and tissue samples from the transplanted liver, to ensure their safety and evaluate how well the treatment is working. The total duration of patient monitoring in the study will be approximately 14 months after receiving the cell treatment.

The research involves testing two different treatments: icatibant and a placebo. Both treatments will be given through intravenous injection, which means they are delivered directly into a vein. The study uses propofol in the form of an injection/infusion solution called Propolipid, along with a salt solution to dilute the medications.

During the study, participants will receive both treatments at different times, and their pain levels will be measured using a special scale. The total duration of treatment for each participant is expected to be very short, lasting only a few days. This is a carefully controlled study where neither the participants nor the healthcare providers know which treatment is being given at any particular time.

The treatment involves a combination of several cancer medications administered through intravenous infusion. These medications include fluorouracil, docetaxel, oxaliplatin, carboplatin, paclitaxel, and folinic acid. These drugs work together to kill cancer cells or stop them from growing. The medications will be given in specific sequences and combinations over several weeks.

The study will examine how well patients respond to this treatment by measuring how long they remain free from cancer progression. The treatment plan includes giving these medications before surgery, which is different from traditional approaches where some treatments are given after surgery. This approach aims to potentially improve outcomes for patients with this type of cancer.